Alectos Therapeutics Inc. is at the forefront of developing innovative small-molecule therapeutics aimed at treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s GBA2 program focuses on enhancing lysosomal function by inhibiting the enzyme glucocerebrosidase 2 (GBA2), which has shown promise in correcting lysosomal dysfunction associated with these diseases. Their lead compound, AL01811, is a selective GBA2 inhibitor that has the potential to serve as an oral disease-modifying treatment for Parkinson’s disease. Alectos has partnered with Biogen to advance this program, which is characterized by drug-like properties including potency, selectivity, and the ability to penetrate the central nervous system.

In addition to the GBA2 program, Alectos is also advancing its O-GlcNAcase (OGA) inhibition strategy, which targets the modulation of O-linked N-acetylglucosamine (O-GlcNAc) residues on proteins. This approach aims to prevent the aggregation of toxic proteins such as tau and α-synuclein, which are implicated in Alzheimer’s and Parkinson’s diseases, respectively. Alectos has previously collaborated with Merck to develop the first clinical OGA inhibitor and is now focusing on advancing its own OGA development candidates. The company’s research indicates that OGA inhibition can lead to increased O-GlcNAc levels, thereby reducing neurodegeneration and protein aggregation in various neurodegenerative models.

Canada

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease.  We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies.  Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Central Nervous System (CNS)

Genetic Diseases

Lymphatic Diseases

Metabolic Diseases

Nervous System Diseases

Psychological Diseases

Alectos Therapeutics Inc.

Alzheimer's disease

Frontotemporal dementia

Ischemic stroke

O-GlcNAcase (OGA) inhibitors

Small Molecule Pharmaceuticals

Parkinson's disease

AL01811 Glucocerebrosidase 2 (GBA) inhibitors

Niemann Pick Disease Type C

Glucocerebrosidase 2 (GBA) inhibitors

Therapeutic

Alectos Therapeutics Inc.

Company Details